Skip to main content

Advertisement

SpringerLink
Log in

Therapeutic peptides revisited

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Abstract

After a roller coaster ride of successes and failures, new discovery technologies and advances in manufacturing promise a brighter future for peptides in human therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: US patient populations for some peptide therapies in development.
Figure 2: Manufacturing costs for bulk peptide production (over 100 kg).
Figure 3

References

  1. http://www.genosys.com/prod01.html; http://www.anaspec.com/custom_fset.html.

  2. Kelly, W.S. Therapeutic peptides: the devil is in the details. Bio/Technology 14, 28—31 ( 1996).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. president of New Venture Advisors , Boston, 02130, MA

    Peter W. Latham

Authors
  1. Peter W. Latham
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Latham, P. Therapeutic peptides revisited. Nat Biotechnol 17, 755–757 (1999). https://doi.org/10.1038/11686

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/11686

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation